Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients

Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients

Background Biomarkers predicting immunotherapy response in metastatic renal cell cancer (mRCC) are lacking. PD-L1 immunohistochemistry is a complementary diagnostic for immune checkpoint inhibitors (ICIs) in mRCC, but has shown minimal clinical utility and is not used in routine clinical practice. M...

Full description

Bibliographic Details
Main Authors: Tian Zhang, Sarabjot Pabla, Felicia L. Lenzo, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Vincent Giamo, Jonathan Andreas, Yirong Wang, Wiam Bshara, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Rajan Gupta, Jason Zhu, Matthew Labriola, Shannon McCall, Daniel J. George, Pooja Ghatalia, Farshid Dayyani, Robert Edwards, Michelle S Park, Rajbir Singh, Robin Jacob, Saby George, Bo Xu, Matthew Zibelman, Razelle Kurzrock, Carl Morrison
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
nivolumab
renal cell carcinoma
pd-1
pd-l1
proliferation
ki-67
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1773200

Internet

http://dx.doi.org/10.1080/2162402X.2020.1773200

Similar Items